Trichostatin A inhibits osteoclastogenesis and bone resorption by suppressing the induction of c-Fos by RANKL

European Journal of Pharmacology

Volumn 623, Issue 1-3, 2009, Pages 22-29

  Kim, Ha Neui ^a   Ha, Hyunil ^a   Lee, Jong Ho ^a   Jung, Kyoungsuk ^a   Yang, Daum ^a   Woo, Kyung Mi ^a   Lee, Zang Hee ^a  

^a School of Dentistry   (South Korea)

Author keywords

Bone destruction; c Fos; Osteoclast differentiation; RANKL; TSA

Indexed keywords

INTERLEUKIN 1; LIPOPOLYSACCHARIDE; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN C FOS; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NFATC1; TRICHOSTATIN A; UNCLASSIFIED DRUG; VORINOSTAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BONE DESTRUCTION; BONE MARROW CELL; CELL DIFFERENTIATION; COCULTURE; CONTROLLED STUDY; DRUG EFFICACY; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MOUSE; NEWBORN; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION;

ANIMALS; BONE MARROW CELLS; BONE NEOPLASMS; BONE RESORPTION; CELL DIFFERENTIATION; CELLS, CULTURED; COCULTURE TECHNIQUES; HISTONE DEACETYLASE INHIBITORS; HYDROXAMIC ACIDS; INTERLEUKIN-1; LIPOPOLYSACCHARIDES; MACROPHAGES; MICE; MICE, INBRED ICR; NFATC TRANSCRIPTION FACTORS; OSTEITIS; OSTEOBLASTS; OSTEOCLASTS; OSTEOPROTEGERIN; PROTO-ONCOGENE PROTEINS C-FOS; RANK LIGAND; SKULL;

EID: 70350182197     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.09.025     Document Type: Article

References (31)

1. Boyle W.J., Simonet W.S., and Lacey D.L. Osteoclast differentiation and activation. Nature 423 (2003) 337-342
2. Butler L.M., Agus D.B., Scher H.I., Higgins B., Rose A., Cordon-Cardo C., Thaler H.T., Rifkind R.A., Marks P.A., and Richon V.M. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res. 60 (2000) 5165-5170
3. Carey N., and La Thangue N.B. Histone deacetylase inhibitors: gathering pace. Curr. Opin. Pharmacol. 6 (2006) 369-375
4. Cheng H.L., Mostoslavsky R., Saito S., Manis J.P., Gu Y., Patel P., Bronson R., Appella E., Alt F.W., and Chua K.F. Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 10794-10799
5. Darnay B.G., Ni J., Moore P.A., and Aggarwal B.B. Activation of NF-κB by RANK requires tumor necrosis factor receptor-associated factor (TRAF) 6 and NF-κB-inducing kinase. J. Biol. Chem. 274 (1999) 7724-7731
6. David J.-P., Mehic D., Bakiri L., Schilling A.F., Mandic V., Priemel M., Idarraga M.H., Reschke M.O., Hoffmann O., Amling M., and Wagner E.F. Essential role of RSK2 in c-Fos-dependent osteosarcoma development. J. Clin. Invest. 115 (2005) 664-672
7. Finzer P., Kuntzen C., Soto U., Hausen H., and Rösl F. Inhibitors of histone deacetylase arrest cell cycle and induce apoptosis in cervical carcinoma cells circumventing human papillomavirus oncogene expression. Oncogene 20 (2001) 4768-4776
8. Galibert L., Tometsko M.E., Anderson D.M., Cosman D., and Dougall W.C. The involvement of multiple tumor necrosis factor receptor (TNFR)-associated factors in the signaling mechanisms of receptor activator of NF-κB, a member of the TNFR superfamily. J. Biol. Chem. 273 (1998) 34120-34127
9. Grigoriadis A.E., Wang Z.Q., Cecchini M.G., Hofstetter W., Felix R., Fleisch H.A., and Wagner E.F. c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science 266 (1994) 443-448
10. Hsu H., Lacey D.L., Dunstan C.R., Solovyev I., Colombero A., Timms E., Tan H.-L., Elliott G., Kelley M.J., Sarosi I., Wnag L., Xia X.-Z., Elliott R., Chiu L., Black T., Scully S., Capparelli C., Morony S., Shimamoto G., Bass M.B., and Boyle W.J. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 3540-3545
11. Janson W., Brandner G., and Siegel J. Butyrate modulates DNA-damage-induced p53 response by induction of p53-independent differentiation and apoptosis. Oncogene 15 (1997) 1395-1406
12. Karsenty G., and Wagner E.F. Reaching a genetic and molecular understanding of skeletal development. Dev. Cell 2 (2002) 389-406
13. Kelly W.K., Richon V., O'Connor O., Curley T., MacGregor-Curtelli B., Tong W., Klang M., Schwartz L., Richardson S., Rosa E., Drobnjak M., Cordon-Cordo C., Chiao J.H., Rifkind R., Marks P.A., and Scher H. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin. Cancer Res. 9 (2003) 3578-3588
14. Lee Z.H., and Kim H.-H. Signal transduction by receptor activator of nuclear factor kappa B in osteoclasts. Biochem. Biophys. Res. Commun. 305 (2003) 211-214
15. Lee S.E., Chung W.J., Kwak H.B., Chung C.-H., Kwack K., Lee Z.H., and Kim H.-H. Tumor necrosis factor-α supports the survival of osteoclasts through the activation of Akt and Erk. J. Biol. Chem. 276 (2001) 49343-49349
16. Matsumoto M., Sudo T., Saito T., Osada H., and Tsujimoto M. Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF-κB ligand (RANKL). J. Biol. Chem. 275 (2000) 31155-31161
17. Matsuo K., Owens J.M., Tonko M., Elliott C., Chambers T.J., and Wagner E.F. Fosl1 is a transcriptional target of c-Fos during osteoclast differentiation. Nat. Genet. 24 (2000) 184-187
18. McLaughlin F., and La Thangue N.B. Histone deacetylase inhibitors open new doors in cancer therapy. Biochem. Pharmacol. 68 (2004) 1139-1144
19. Monneret C. Histone deacetylase inhibitors. Eur. J. Med. Chem. 40 (2005) 1-13
20. Platta C.S., Greenblatt D.Y., Kunnimalaiyaan M., and Chen H. The HDAC inhibitor trichostatin A inhibits growth of small cell lung cancer cells. J. Surg. Res. 142 (2007) 219-226
21. Rahman M.M., Kukita A., Kukita T., Shobuike T., Nakamura T., and Kohashi O. Two histone deacetylase inhibitors, trichostatin A and sodium butyrate, suppress differentiation into osteoclasts but not into macrophages. Blood 101 (2003) 3451-3459
22. Rodan G.A., and Martin T.J. Therapeutic approaches to bone diseases. Science 289 (2000) 1508-1514
23. Sakuma Y., Tanaka K., Suda M., Yasoda A., Natsui K., Tanaka I., Uchikubi F., Narumiya S., Segi E., Sugimoto Y., Ichikawa A., and Nakao K. Crucial involvement of the EP4 subtype of prostaglandin E receptor in osteoclast formation by proinflammatory cytokines and lipopolysaccharide. J. Bone Miner. Res. 15 (2000) 218-227
24. Suda T., Takahashi N., and Martin T.J. Modulation of osteoclast differentiation. Endocr. Rev. 13 (1992) 66-80
25. Suda T., Takahashi N., Udagawa N., Jimi E., Gillespie M.T., and Martin T.J. Modulation of osteoclast differentiation and function by the new member of the tumor necrosis factor receptor and ligand families. Endocr. Rev. 20 (1999) 345-357
26. Takayanagi H., Kim S., Koga T., Nishina H., Isshiki M., Yoshida H., Saiura A., Isobe M., Yokochi T., Inoue J.-i., Wagner E.F., Mak T.W., Kodama T., and Taniguchi T. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev. Cell 3 (2002) 889-901
27. Teitelbaum S.L., and Ross F.P. Genetic regulation of osteoclast development and function. Nat. Rev. 4 (2003) 638-649
28. Thalhamer T., McGrath M.A., and Harnett M.M. MAPKs and their relevance to arthritis and inflammation. Rheumatology 47 (2008) 409-414
29. Vigushin D.M., Ali S., Pace P.E., Mirsaidi N., Ito K., Adcock I., and Coombes R.C. Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin. Cancer Res. 7 (2001) 971-976
30. Wong B.R., Besser D., Kim N., Arron J.R., Vologodskaia M., Hanafusa H., and Choi Y. TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src. Mol. Cell 4 (1999) 1041-1049
31. Yoshida M., Kijima M., Akita M., and Beppu T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J. Biol. Chem. 265 (1990) 17174-17179